文献速递毛发、甲与色素性疾病

跨性别与性别多元人群雄激素性脱发发病率:一项回顾性比较队列研究

Androgenetic alopecia incidence in transgender and gender diverse populations: A retrospective comparative cohort study.
PubMed 文献 · J Am Acad Dermatol · 2023-02-11

该回顾性队列研究利用Fenway Health 2014年8月1日至2020年8月1日就诊的37,826例患者电子健康记录,比较接受性别肯定激素治疗的跨性别与性别多元(TGD)患者与顺性别患者的雄激素性脱发(AGA)发病率。结果显示,接受男性化GAHT的TGD患者AGA发病率较顺性别女性高(aIRR 2.50,95% CI 1.71-3.65),较顺性别男性无显著差异(aIRR 1.30,95% CI 0.91-1.86);接受女性化GAHT的TGD患者AGA发病率较顺性别男性无显著差异,但较顺性别女性显著升高(aIRR 1.91,95% CI 1.25-2.92)。

要点

  • 接受男性化GAHT的TGD患者AGA发病率是顺性别女性的2.5倍(aIRR 2.50,95% CI 1.71-3.65)。
  • 接受男性化GAHT的TGD患者AGA发病率与顺性别男性无显著差异(aIRR 1.30,95% CI 0.91-1.86)。
  • 接受女性化GAHT的TGD患者AGA发病率较顺性别女性显著升高(aIRR 1.91,95% CI 1.25-2.92),与顺性别男性无显著差异。

核心结论

  • 接受男性化GAHT的TGD患者AGA发病率是顺性别女性的2.5倍,而接受女性化GAHT的TGD患者AGA发病率较顺性别男性无显著升高。

研究设计与样本

  • 回顾性比较队列研究,使用Fenway Health 2014年8月1日至2020年8月1日就诊的37,826例患者电子健康记录。
  • 采用泊松回归计算AGA的粗发病率比和调整发病率比(aIRR)。

主要发现

  • 接受男性化GAHT的TGD患者与顺性别女性相比AGA的aIRR为2.50(95% CI 1.71-3.65),与顺性别男性相比aIRR为1.30(95% CI 0.91-1.86)。
  • 接受女性化GAHT的TGD患者AGA发病率与顺性别男性无显著差异,但与顺性别女性相比aIRR为1.91(95% CI 1.25-2.92)。

局限性

  • 无法确定因果关系。
  • 普遍性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Androgenetic alopecia (AGA) is a significant challenge for many transgender and gender diverse (TGD) patients, but the rate of AGA among TGD patients receiving gender-affirming hormone therapy (GAHT) compared to cisgender patients has not yet been studied on a large scale. OBJECTIVE: We examined the incidence of AGA among TGD patients receiving GAHT compared to cisgender patients. METHODS: Retrospective cohort study using electronic health records from 37,826 patients seen at Fenway Health between August 1, 2014, and August 1, 2020. Crude and adjusted incidence rate ratios (aIRR) for AGA were calculated using Poisson regression. RESULTS: TGD patients receiving masculinizing GAHT had aIRR 2.50, 95% CI 1.71-3.65 and 1.30, 95% CI 0.91-1.86 compared to cisgender women and cisgender men, respectively. The rate of AGA for TGD patients receiving feminizing GAHT was not significantly different compared to cisgender men but was significantly increased compared to cisgender women (aIRR 1.91, 95% CI 1.25-2.92). LIMITATIONS: Inability to determine causation and limited generalizability. CONCLUSION: TGD patients receiving masculinizing GAHT have 2.5 times the rate of AGA compared to cisgender women, whereas TGD patients on feminizing GAHT did not have a significantly increased rate of AGA compared to cisgender men.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Gao JL, Sanz J, Tan N, et al. Androgenetic alopecia incidence in transgender and gender diverse populations: A retrospective comparative cohort study. J Am Acad Dermatol. 2023. PMID: 36780950. doi:10.1016/j.jaad.2023.01.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。